The call for applications has begun for the medical research agency’s competition for non-commercial clinical trials in psychiatry and neuroscience. The competition aims to support the National Mental Health Program.

The call for applications starts on May 5, 2021, from 12.00 until June 30, 2021, until it can only be submitted in the form of an electronic document via the information and communication technology system available on the agency’s website: https://konkurs.abm.gov.pl/#/.

Questions related to the competition should be sent to the following email address: [email protected].

In order to receive additional information about the competition assumptions, about preparing and submitting applications, you may participate in a webinar organized by ABM – after pre-registration. Information on this topic is available at: https://www.abm.gov.pl/pl/aktualnosci/wydarzenia-i-szkolenia/14,quotZasady-ubiegania-sie-o-doffinansowanie-na-niekomercyjne-badania-kliniczne- wo .html

In the information sent to PAP, ABM notes that the number of mental disorders and neurological problems in the world has increased significantly in recent years.

“Given the rate of population aging and the prevalence of risk factors, neurological and mental diseases have become a serious medical and social problem,” she added.

The aim of the competition is to develop new diagnostic and therapeutic procedures in psychiatry and neuroscience as part of non-commercial clinical trials. It will support the National Mental Health Program.

The statement also notes that research like this is of particular relevance in the context of the ongoing COVID-19 pandemic.

“As researchers’ observations published in the Lancet Psychiatry + showed, a third of patients who develop COVID-19 are diagnosed with neurological or mental disorders within six months of being infected. This indicates that the pandemic could trigger a wave of psychological and neurological problems in the future. Near “- reported ABM.

The ABM program aims to contribute to improving the condition of patients suffering from mental and neurological diseases, mainly due to the increased availability of modern diagnostic and treatment methods. The competition is conducted according to the Clinical Trials Development Plan for the period 2020-2025 (PAP)

Author: Iwona Pałczyńska

ipa / nut /